Neutral.
• Q3 revenue €3,070m +2% organic, -5% reported. In line with expectations.
• EBITDA €540m flat.
• Reducing Adj EBITDA outlook to €2.3bn from ~€2.4bn reflecting €90m FX effect and €50m lower ANH contribution.
• Animal Health sale should conclude in Q4.
• Adj EBITDA Margin 20% ex ANH. This is up from 19.4% H1 25 and 15.5% H1 24
Find more articles and bullets on these widgets:
0RV5 98.00/98.0625cs, bought for 1.25 in 5k.
SFIF6 96.25/96.15ps 1x2, bought for 1.5 in 1k.
Trend signals in Silver remain bullish. The metal traded higher on Monday as the bull cycle extends. Note that moving average studies are in a bull-mode position too, reinforcing current conditions. Sights are $47.251 next, a 2.382 projection of the Sep 4 - 16 - 17 price swing. Clearance of this level would pave the way for a climb towards $47.857, the 2.618 projection. Initial firm support to watch lies at $42.933, the 20-day EMA.